PDE/TRPA1/CHIT1-IN-1

PDE/TRPA1/CHIT1-IN-1 是一种 PDEs、TRPA1 及 hCHIT1(KD 值为 37.7 μM)抑制剂,也是一种广谱 PDE 抑制剂,可强效作用于包括 PDE4B、PDE7A、PDE3A 和 PDE8A 在内的关键亚型,其 IC50 值分别为 15.54、15.15、8.39 和 16.46 μM,并能抑制 NLRP3 炎症小体激活、阻断 NF-κB 磷酸化,从而下调体内促炎基因(TNF-α 和 IL-6)的表达,可用于慢性阻塞性肺疾病及相关炎症性肺病的研究。
PDE/TRPA1/CHIT1-IN-1
产品编号: MS-U97178 分子式: C28H33N7O5 分子量: 547.61
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PDE/TRPA1/CHIT1-IN-1 是一种 PDEs、TRPA1 及 hCHIT1(KD 值为 37.7 μM)抑制剂,也是一种广谱 PDE 抑制剂,可强效作用于包括 PDE4B、PDE7A、PDE3A 和 PDE8A 在内的关键亚型,其 IC50 值分别为 15.54、15.15、8.39 和 16.46 μM,并能抑制 NLRP3 炎症小体激活、阻断 NF-κB 磷酸化,从而下调体内促炎基因(TNF-α 和 IL-6)的表达,可用于慢性阻塞性肺疾病及相关炎症性肺病的研究。

生物实验数据

生物活性 PDE/TRPA1/CHIT1-IN-1 is an inhibitor of PDEs, TRPA1, and hCHIT1 (KD = 37.7 μM), and a broad-spectrum PDE inhibitor that potently acts on key subtypes including PDE4B, PDE7A, PDE3A, and PDE8A with IC50 values of 15.54, 15.15, 8.39, and 16.46 μM, respectively; it inhibits NLRP3 inflammasome activation and blocks NF-κB phosphorylation, thereby downregulating the expression of pro-inflammatory genes (TNF-α and IL-6) in vivo, and can be used for research on chronic obstructive pulmonary disease and related inflammatory lung diseases.
IC50 & Target

PDE4B

15.54 μM (IC50)

PDE7A

15.15 μM (IC50)

PDE3A

8.39 μM (IC50)

PDE8A

16.64 μM (IC50)

PDE1B

54.47 μM (IC50)

PDE2A

79.61 μM (IC50)

PDE4D

130.50 μM (IC50)

PDE5A

26.86 μM (IC50)

PDE10A

36.13 μM (IC50)

体外研究
(In Vitro)

PDE/TRPA1/CHIT1-IN-1 (compound 39) (10 μM,1 小时) 在 Lipopolysaccharides (LPS) (MS-X54539) 刺激的 RAW264.7 巨噬细胞中具有抗炎活性。
PDE/TRPA1/CHIT1-IN-1 抑制 PDE1B、PDE2A、PDE4B、PDE7A、PDE3A、PDE4D、PDE5A、PDE8A 和 PDE10A,其 IC50 值分别为 54.47、79.61、15.54、15.15、8.39、130.50、26.86、16.46 和 36.13 μM。
PDE/TRPA1/CHIT1-IN-1 (1-50 μM,1 小时) 抑制支气管平滑肌细胞增生与肥大,减少 BSMC 和 MRC-5 细胞的细胞外基质成分分泌,并抑制成纤维细胞向肌成纤维细胞的转化。
PDE/TRPA1/CHIT1-IN-1 具有支气管舒张效应,IC50 值为 1.56 μM,并对预收缩的大鼠气管段产生最大舒张率达 100%。
PDE/TRPA1/CHIT1-IN-1 具有高代谢稳定性 (t1/2 = 53.42 分钟,固有清除率 Clint = 32.43 μL/min/mg)、可忽略的肝细胞毒性 (在 HepG2 细胞中 IC50 = 34.70 μM) 和中等的膜渗透性 (logPe = -5.305)。

ELISA Assay

Cell Line: LPS-stimulated RAW264.7 macrophages
Concentration: 10 μM
Incubation Time: 1 h
Result: Caused an almost twofold reduction in TNF-α and IL-6 levels in LPS-induced RAW264.7 cells, lowering TNF-α concentrations to 381.74 pg/mL and decreasing IL-6 concentrations to 141.02 pg/mL.

Cell Proliferation Assay

Cell Line: FBS induced-MRC-5, FBS induced-BSMC, TGF-β induced- MRC-5 and TGF-β induced-BSMC
Concentration: 1, 10 and 50 μM
Incubation Time: 1 h
Result: Reduced BSMC and MRC-5 proliferation by 38 % and 32 % at a concentration of 10 μM.
Reduced TGF-β-induced expression of COL1A1 and FN1 genes in both cell lines.
Decreased TGF-β-induced ACTA2 expression in BSMCs by almost a 3-fold.
Reduce TGF-β-induced ACTA2 expression in lung fibroblasts.
体内研究
(In Vivo)

PDE/TRPA1/CHIT1-IN-1 (compound 39) (25 mg/kg,腹腔注射,每日一次,持续 2 周) 在弹性蛋白酶诱导的肺气肿模型中显示出抗炎特性并调控 NLRP3 炎症小体。

Animal Model: PPE (MS-T90311) (intranasally,i.n. once a week for 4 week) induced-Balb/c male mice (8-10 weeks, 23-25 g)
Dosage: 25 mg/kg
Administration: i.p., once daily; for 2 weeks
Result: Protected against elastase-induced emphysema with a mean linear intercept (MLI) values of 50.36 μM.
Ameliorated the elastase-induced increase in total inflammatory cells in in bronchoalveolar lavage fluid (BALF).
Reduced the total number of all inflammatory cells in BALF collected from the PPE-induced model.
Acted as a relatively strong inhibitor of PDE7A and PDE3A, as well as a TRPA1 antagonist.
Reduced the PPE-induced transcript levels of key inflammatory genes in lung homogenates to control levels.
Decrease in Tnfa, Cxcl2, Il6, and Il1b expression.
Limited the levels of NLRP3 inflammasome components and consequently reduced the activation of NLRP3 inflammasome components.
Reduced the PPE-induced level of cleaved caspase-1, which may have inhibited the formation of interleukin 1β (IL-1β), a hallmark cytokine of NLRP3 inflammasome activation.
Reduced NF-κB phosphorylation, as well as the expression of various proinflammatory genes, including Tnfa, Cxcl2, Il6, and Il1b.

化学信息

分子量 547.61
分子式 C28H33N7O5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础